- Ọgwụgwọ
- Ihe akaebe
- Neuroblastoma
- Ọrịa siri ike
- Ihe akaebe
- TILS
- Ọgwụgwọ NK Cell
- Myasthenia Gravis (MG)
- Ọrịa kansa ọbara Lymphoblastic dị oke njọ (B-ALL)
- Ọrịa Lupus Erythematosus Sistemụ (SLE)
- Ọrịa kansa ọbara Lymphoblastic dị oke njọ (T-ALL)
- Ọrịa Lymphoma na-abụghị Hodgkin (NHL)
- Ọtụtụ Myeloma (MM)
- Lymphom B-cell buru ibu nke gbasaara agbasa
- Ọrịa kansa ọbara B-lymphocytic
- Myeloma
Ọrịa kansa ọbara Lymphoblastic dị oke njọ (T-ALL)-03
Atụmatụ ikpe:
- Nchọpụta: Ọrịa leukemia lymphoblastic T-cell dị egwu
- Mmalite na Ihe Mgbaàmà: Eprel 2020, nke nwere isi ọwụwa, ike ọgwụgwụ, na ebe ọbara na-agba n'akpụkpọ ahụ. A chọpụtara ya na ọrịa leukemia lymphoblastic T-cell dị njọ site na nyocha MICM nke ụmị ọkpụkpụ.
- Ọgwụgwọ Mbụ: Emere mweghachi zuru oke (CR) mgbe usoro ọgwụgwọ VDCLP gasịrị, wee soro usoro ọgwụgwọ chemotherapy siri ike ugboro abụọ.
- Julaị 19, 2020: E nyere m mgbanwe mkpụrụ ndụ hematopoietic allogeneic site n'aka onye na-enye onyinye nwanyị (HLA 5/10 A onye na-enye onyinye A). Usoro nhazi ahụ gụnyere radieshon ahụ dum (TBI), cyclophosphamide (CY), na etoposide (VP-16). A gbara mkpụrụ ndụ akụkụ dị n'akụkụ na Julaị 24, na-agbake site na ụbọchị +10 na ntinye platelet site na ụbọchị +13. Mgbe nke ahụ gasịrị, a na-eme nyocha mgbe niile n'ụlọ ọgwụ.
- Febụwarị 25, 2021: Achọpụtara nlọghachi nke ụmị ọkpụkpụ n'oge a na-enyocha ya.
Ọgwụgwọ: Amalitela ọgwụgwọ thalidomide n'ọnụ.
- Machị 8: E tinyere ya n'ụlọ ọgwụ anyị.
- Ọkwa ọkpụkpụ: 61.5% mgbawa.
- Nkewa Ọbara Mpụta: 15% nke mgbawa.
- Immunophenotyping: 35.25% mkpụrụ ndụ na-egosipụta CD99, CD5, CD3dim, CD8dim, CD7, cCD3, CD2dim, HLA-ABC, cbcl-2, CD81, CD38, nke na-egosi lymphocytes T ndị na-adịghị ike.
- Nnyocha Krọmosọm: 46, XX [9].
- Mkpụrụ ndụ ihe nketa Leukemia Fusion: Mkpụrụ ndụ ihe nketa SIL-TAL1 fusion positive; nha nha: SIL-TA.
- Mgbanwe nke Tumor Ọbara: Ihe na-adịghị mma.
- Nyocha Chimerism (mgbe HSCT gasịrị): Mkpụrụ ndụ sitere na ndị nyere onyinye ruru 45.78%.
- Machị 11: Nchịkọta nke sel sel CD7-CART maka imepụta sel ndị na-anaghị arụ ọrụ nke ọma.
- Ọgwụgwọ: VILP (VDS 4mg, IDA 10mg, L-asparaginase 10,000 IU qd x ụbọchị 4, Dex 9mg q12h x ụbọchị 9) yana thalidomide iji chịkwaa etuto ahụ.
- Machị 19: Usoro ọgwụgwọ FC (Flu 50mg x ụbọchị 3, CTX 0.4gx ụbọchị 3).
- Machị 24 (tupu a gbanye ya): Ọdịdị ọkpụkpụ gosiri hyperplasia ọkwa V, yana 22% mgbawa.
- Cytometry nke Ọkpụkpụ Mbara: 29.21% mkpụrụ ndụ (nke mkpụrụ ndụ nucleated) na-egosipụta CD3, CD5, CD7, CD99, na-egosipụta cCD3 nke ọma, na-egosi mkpụrụ ndụ T ndị na-etobeghị eto.
- Mkpụrụ ndụ ihe nketa SIL-TAL1 nke ọnụọgụgụ: 1.913%.
nkọwa2
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.